BCNI researchers based in Galway and their collaborators have published significant new findings in the journal “Leukemia”.
The researchers have shown that Myeloma cells that express high levels of the E-selectin ligand give rise to a more aggressive disease and were more resistant to chemotherapy. They also found that relapsed patients had higher levels of E-selectin expressing cells.Significantly they went on to demonstrate that by using an E-selectin antogonist (GM1271) they could prevent the cells becoming resistant to chemotherapy.
This work work is important because it provides a rational for targeting E-selectin receptor/ligand interactions to overcome metastasis and chemoresistance in Multiple Myeloma.
leukemia paper accepted article